Reinforcing the primary immunotherapy modulators against acute leukemia; monoclonal antibodies in AML.
作者： Mehrdad Mahalleh , Mahsima Shabani , Elham Rayzan , Nima Rezaei
关键词:
摘要: Recent therapeutic advances in cancer treatment recruit immune system potentiation against malignant cells. Numerous ongoing clinical trials on immunotherapy methods, either monotherapy or combination therapy, are investigating the impeding factors way of acute myeloid leukemia (AML) treatment. Due to genetic diversity AML progenitors, combining various strategies is more likely be useful for improving patient outcomes. This review describes details applying monoclonal antibodies AML, focusing CD33, CD123, FLT3, CD45 and CD66 targeting. Furthermore, it clarifies importance immunotoxins, bispecific antibodies, chimeric antigen receptor (CAR)-T cells T cell receptor-modified as reinforcing agents antibodies.
sci-hub.se 参考文章(116)
Roland B. Walter, Oliver W. Press, Irwin D. Bernstein, Antibody-Based Therapeutics Targeting CD33, CD45, and CD66 Springer, New York, NY. pp. 531- 555 ,(2015) , 10.1007/978-1-4939-1393-0_27
Cancer Genome Atlas Research Network, None, Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia The New England Journal of Medicine. ,vol. 368, pp. 2059- 2074 ,(2013) , 10.1056/NEJMOA1301689
Paul Carter, Improving the efficacy of antibody-based cancer therapies Nature Reviews Cancer. ,vol. 1, pp. 118- 129 ,(2001) , 10.1038/35101072
Dolores A. Grosso, Rosemary C. Hess, Mark A. Weiss, Immunotherapy in acute myeloid leukemia Cancer. ,vol. 121, pp. 2689- 2704 ,(2015) , 10.1002/CNCR.29378
Go J. Yoshida, Hideyuki Saya, Therapeutic strategies targeting cancer stem cells. Cancer Science. ,vol. 107, pp. 5- 11 ,(2016) , 10.1111/CAS.12817
Peter F Bross, Julie Beitz, Gang Chen, Xiao Hong Chen, Eric Duffy, Lydia Kieffer, Sandip Roy, Rajeshwari Sridhara, Atiqur Rahman, Grant Williams, Richard Pazdur, None, Approval Summary: Gemtuzumab Ozogamicin in Relapsed Acute Myeloid Leukemia Clinical Cancer Research. ,vol. 7, pp. 1490- 1496 ,(2001)
Hans J Stauss, Emma C Morris, Hinrich Abken, Cancer gene therapy with T cell receptors and chimeric antigen receptors Current Opinion in Pharmacology. ,vol. 24, pp. 113- 118 ,(2015) , 10.1016/J.COPH.2015.08.006
Louis M. Weiner, Joseph C. Murray, Casey W. Shuptrine, Antibody-Based Immunotherapy of Cancer Cell. ,vol. 148, pp. 1081- 1084 ,(2012) , 10.1016/J.CELL.2012.02.034
Brandon G. Smaglo, Dalal Aldeghaither, Louis M. Weiner, The development of immunoconjugates for targeted cancer therapy Nature Reviews Clinical Oncology. ,vol. 11, pp. 637- 648 ,(2014) , 10.1038/NRCLINONC.2014.159
Todd L. Rosenblat, Michael R. McDevitt, Deborah A. Mulford, Neeta Pandit-Taskar, Chaitanya R. Divgi, Katherine S. Panageas, Mark L. Heaney, Suzanne Chanel, Alfred Morgenstern, George Sgouros, Steven M. Larson, David A. Scheinberg, Joseph G. Jurcic, Sequential Cytarabine and α-Particle Immunotherapy with Bismuth-213–Lintuzumab (HuM195) for Acute Myeloid Leukemia Clinical Cancer Research. ,vol. 16, pp. 5303- 5311 ,(2010) , 10.1158/1078-0432.CCR-10-0382